The Zacks Analyst Blog Highlights:Bayer, Novartis, Pfizer, Onyx Pharmaceuticals and Boeing

       The Zacks Analyst Blog Highlights:Bayer, Novartis, Pfizer, Onyx
                          Pharmaceuticals and Boeing

PR Newswire

CHICAGO, Nov. 1, 2012

CHICAGO, Nov. 1, 2012 /PRNewswire/ --Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Bayer (OTC:BAYRY), Novartis
(NYSE:NVS), Pfizer (NYSE:PFE), Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX) and
The Boeing Company (NYSE:BA).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday's Analyst Blog:

Priority FDA Review for Stivarga

Recently, the HealthCare unit of Bayer (OTC:BAYRY) announced that its oncology
drug Stivarga (regorafenib) will be reviewed on a priority basis by the US
Food and Drug Administration (FDA). Bayer is looking to get Stivarga, an oral
multi-kinase inhibitor, approved for treating patients suffering from
metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

We note that the US regulatory authority generally reviews those drugs on a
priority basis, which offer major advances in treating diseases that do not
have adequate therapy. Applications for priority review designated drugs are
reviewed by the FDA within six months of submission as against the usual ten
months.

The new drug application (NDA), seeking approval of Stivarga for the GIST
indication, was filed by Bayer in August 2012. The NDA was submitted on the
basis of encouraging data from a phase III study (GRID: n=199), which
evaluated patients suffering from metastatic and/or unresectable GIST. The
disease had progressed in the evaluated patients in spite of being previously
treated with Novartis' (NYSE:NVS) Gleevec and Pfizer's (NYSE:PFE) Sutent.

We remind investors that Stivarga was approved in the US in September 2012 for
treating patients suffering from metastatic colorectal cancer (mCRC), whose
disease had progressed even after treatment with the standard drugs prescribed
for the disease. The approval was based on encouraging data from a pivotal
phase III study (CORRECT: n=760). Bayer and

Onyx Pharmaceuticals, Inc.

(Nasdaq:

ONXX

), as per an agreement inked last year, co-promote Stivarga in the US.

The sales potential of Stivarga would be further boosted if the FDA clears the
drug for the GIST indication.

Our Recommendation

We have an Outperform recommendation on Bayer. The stock carries a Zacks #2
Rank (Buy rating) in the short run.

Boeing Gets Multi-Billion MAX Order

Leading commercial airplane producer, The Boeing Company (NYSE:BA) received a
multi-billion order for its 737 MAX model from Aviation Capital Services LLC,
a subsidiary of the State Corporation Russian Technologies (Rostech).

Rostech announced a commitment to purchase 35 737 MAX airplanes for Russia and
the Commonwealth of Independent States ("CIS"). The order is valued at more
than $3 billion at current list prices.

The 737 MAX is a new-engine variant of the world's best-selling airplane and
builds on the strengths of today's Next-Generation 737. The 737 MAX
incorporates the latest-technology CFM International LEAP-1B engines to
deliver the highest efficiency, reliability and passenger comfort in the
single-aisle market. As per Boeing, airlines operating the 737 MAX will see a
13% fuel-use improvement over today's most fuel efficient single-aisle
airplanes and an 8% operating cost per seat advantage over tomorrow's
competition. Boeing currently has 858 orders for the 737 MAX.

Aviation Capital Services LLC is one of the leading aircraft leasing companies
in Russia and CIS.

Boeing enjoys a unique position as the largest aircraft manufacturer in the
world in terms of revenues, orders and deliveries, and is also one of the
largest aerospace and defense contractors. Besides, its revenues are spread
across more than 90 countries around the globe.

Looking forward, Boeing recently taking into account its performance in the
first nine months of 2012, raised its full year 2012 earnings per share
guidance to a range of $4.80–$4.95 from its earlier guidance range of
$4.40–$4.60. The company also raised its revenue guidance for 2012 to the
range of $80.5 billion – $82 billion versus the earlier range of $79.5
billion–$81.5 billion.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter: http://at.zacks.com/?id=5515.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today: http://at.zacks.com/?id=5517

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at http://at.zacks.com/?id=5518.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
 
Press spacebar to pause and continue. Press esc to stop.